These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31414352)

  • 21. A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.
    Kelty E; Hulse G
    Drugs; 2017 Jul; 77(11):1199-1210. PubMed ID: 28536980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and Treatment of Opioid Use Disorder in 2020.
    Wakeman SE
    JAMA; 2020 May; 323(20):2082-2083. PubMed ID: 32329798
    [No Abstract]   [Full Text] [Related]  

  • 24. Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
    Sharma A; Kelly SM; Mitchell SG; Gryczynski J; O'Grady KE; Schwartz RP
    Curr Psychiatry Rep; 2017 Jun; 19(6):35. PubMed ID: 28526967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medication-assisted treatment for youth with opioid use disorder: Current dilemmas and remaining questions.
    Chang DC; Klimas J; Wood E; Fairbairn N
    Am J Drug Alcohol Abuse; 2018; 44(2):143-146. PubMed ID: 29190156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scaling Emergency Department Opioid Use Disorder Treatment Across California to Reduce Overdose Deaths, 2019-2023.
    Samuels EA; Rosen AD; Speener M; Kaleekal J; Kalmin MM; Goodman-Meza D; Shoptaw S; Clayton S; Lin C; Campbell A; Moulin A; Herring AA
    Am J Public Health; 2024 Sep; 114(9):874-878. PubMed ID: 38935888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.
    ; Donohue JM; Jarlenski MP; Kim JY; Tang L; Ahrens K; Allen L; Austin A; Barnes AJ; Burns M; Chang CH; Clark S; Cole E; Crane D; Cunningham P; Idala D; Junker S; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Pauly N; Sheets L; Talbert J; Zivin K; Gordon AJ; Kennedy S
    JAMA; 2021 Jul; 326(2):154-164. PubMed ID: 34255008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in Buprenorphine Treatment in the United States, 2009-2018.
    Olfson M; Zhang VS; Schoenbaum M; King M
    JAMA; 2020 Jan; 323(3):276-277. PubMed ID: 31961408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.
    Chou R; Ballantyne J; Lembke A
    Ann Intern Med; 2019 Sep; 171(6):427-429. PubMed ID: 31450240
    [No Abstract]   [Full Text] [Related]  

  • 31. Sustained Implementation of a Multicomponent Strategy to Increase Emergency Department-Initiated Interventions for Opioid Use Disorder.
    Lowenstein M; Perrone J; Xiong RA; Snider CK; O'Donnell N; Hermann D; Rosin R; Dees J; McFadden R; Khatri U; Meisel ZF; Mitra N; Delgado MK
    Ann Emerg Med; 2022 Mar; 79(3):237-248. PubMed ID: 34922776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergency Department Initiation of Buprenorphine for Opioid Use Disorder: Current Status, and Future Potential.
    Fox L; Nelson LS
    CNS Drugs; 2019 Dec; 33(12):1147-1154. PubMed ID: 31552608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naloxone Administration in US Emergency Departments, 2000-2011.
    Frank JW; Levy C; Calcaterra SL; Hoppe JA; Binswanger IA
    J Med Toxicol; 2016 Jun; 12(2):148-56. PubMed ID: 26621354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Growth and Distribution of Buprenorphine-Waivered Providers in the United States, 2007-2017.
    McBain RK; Dick A; Sorbero M; Stein BD
    Ann Intern Med; 2020 Apr; 172(7):504-506. PubMed ID: 31905379
    [No Abstract]   [Full Text] [Related]  

  • 35. Opioid Use Disorder and Pregnancy.
    O'Donnell FT; Jackson DL
    Mo Med; 2017; 114(3):181-186. PubMed ID: 30228577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of Opioid Overdose.
    Babu KM; Brent J; Juurlink DN
    N Engl J Med; 2019 Jun; 380(23):2246-2255. PubMed ID: 31167053
    [No Abstract]   [Full Text] [Related]  

  • 37. Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States.
    Hochheimer M; Unick GJ
    Addict Behav; 2022 Jan; 124():107113. PubMed ID: 34543869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. College students' perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities.
    Andraka-Christou B; Nguyen T; Harris S; Madeira J; Totaram R; Randall-Kosich O; Atkins D; Ford J
    Am J Drug Alcohol Abuse; 2020 Sep; 46(5):589-603. PubMed ID: 32543922
    [No Abstract]   [Full Text] [Related]  

  • 39. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
    Parrino MW; Maremmani AG; Samuels PN; Maremmani I
    J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Buprenorphine Dispensing after Elimination of the Waiver Requirement.
    Chua KP; Bicket MC; Bohnert ASB; Conti RM; Lagisetty P; Nguyen TD
    N Engl J Med; 2024 Apr; 390(16):1530-1532. PubMed ID: 38657250
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.